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Abstract Pathogenic variants in the PCDH19 gene are
associated with epilepsy, intellectual disability (ID) and
behavioural disturbances. Only heterozygous females and
mosaic males are affected, likely due to a disease
mechanism named cellular interference. Until now, only four
affected mosaic male patients have been described in
literature. Here, we report five additional male patients, of
which four are older than the oldest patient reported so far.
All reported patients were selected for genetic testing because
of developmental delay and/or epilepsy. Custom-targeted next
generation sequencing gene panels for epilepsy genes were
used. Clinical data were collected from medical records. All
patients were mosaic in blood for likely pathogenic variants in
the PCDH19 gene. In most, clinical features were very similar
to the female phenotype, with normal development before
seizure onset, which occurred between 5 and 10 months of
age, clustering of seizures and sensitivity to fever. Four out of
five patients had mild to severe ID and behavioural problems.
We reaffirm the similarity between male and female
PCDH19-related phenotypes, now also in a later phase of
the disorder (ages 10–14 years).
Keywords PCDH19 . Mosaicism . Epilepsy . Intellectual
disability
Introduction
Pathogenic variants in PCDH19 are associated with early on-
set, clustered epileptic seizures often provoked by fever, intel-
lectual disability (ID) that can be present in variable degrees
and behavioural disturbances such as autistic features,
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attention deficit, hyperactivity and aggression. The clinical
features may resemble those of Dravet syndrome (phenotype
MIM # 300088) [1–5].
PCDH19 is located at Xq22.1 and codes for protocadherin-
19, a transmembrane protein involved in neuronal organization
and migration and cell-cell and cell-matrix adhesion [6–10]. It
is highly expressed in the central nervous system [1].PCDH19-
related epilepsy shows a remarkable inheritance pattern: gener-
ally, females carrying heterozygous pathogenic variants are af-
fected, whereas hemizygous male carriers are asymptomatic or
only show psychiatric or behavioural symptoms [1, 2, 11, 12].
However, in 2009, the first affected malemosaic for aPCDH19
pathogenic variant was described [2]. This finding gave rise to a
theory of cellular interference as disease mechanism: disease
occurs when two different cell populations exist (cells express-
ing the normal PCDH19 protein and cells expressing a mutant
form of the protein), as is true for heterozygous and mosaic
pathogenic variants, but not for hemizygous pathogenic vari-
ants in males. These non-homogeneous cell populations are
likely to disrupt cell-cell interactions, leading to disease [2].
Only four affected mosaic male patients have been de-
scribed in literature until now, the oldest being 7 years old
[2, 13, 14]. Here, we report five additional male patients with
mosaic PCDH19mutations, of ages 2, 10, 13, 13 and 14 years
old. We compared the male and female phenotypes.
Methods
Patients and molecular analysis
All five patients were selected for diagnostic genetic testing
because of developmental delay and/or epilepsy. Genetic test-
ing on DNA from lymphocytes was performed using a custom
targeted next generation sequencing (NGS) gene panel for ep-
ilepsy genes (see online resource 1 for details). Mosaicism of
PCDH19 variants was determined based on the simultaneous
presence of a variant allele and the reference allele, as
PCDH19 is located on the X-chromosome and all patients
were male. The percentage of mosaicism was based on the
percentage of reads that showed the alternate allele. PCDH19
mosaic male patients from different centres were collected
through personal communication between authors, meaning
no structured cohort was tested. Detailed clinical data were
collected frommedical records. The parents of all patients gave
informed consent for the publication of clinical data.
Literature search
A literature study was carried out in the PubMed database to




All five patients carried a PCDH19 variant in various degrees
of mosaicism (patient A: c.1864G > C, p.Gly622Arg, 60%;
patient B: c.840C > G, p.Tyr280*, 22%; patient C:
c.462C > G, p.Tyr154*, 65%; patient D: c.1682C > G,
p.Pro561Arg, 78%; patient E: c.799G > T p.Glu267*, 20%,
RefSeq NM_001184880). According to American College of
Medical Genetics and Genomics (ACMG) criteria, the variant
of patient Awas classified as likely pathogenic, and the vari-
ants of patient B-Dwere classified as pathogenic. The variants
of patient B, C and E lead to a premature stopcodon; the
variants of patient A and D were both predicted probably
damaging and damaging by PolyPhen and SIFT, respectively.
None of the variants was present in control databases
(Database of Single Nucleotide Polymorphisms (dbSNP),
NHLBI Exome Sequencing Project (ESP) and the the
Exome Aggregation Consortium (ExAC) database). The
Pro561Arg variant has been previously described in two af-
fected female siblings with ID, microcephaly and seizures and
was paternally transmitted [15]; the other variants are novel.
All variants were confirmed de novo, except for the variant in
patient D, whose parents were not tested. No other variants
that could explain the phenotypes were found.
Clinical characteristics of the newly reported and previous-
ly described male patients with de novo PCDH19 pathogenic
variants are summarized and compared to those of previously
published females in Table 1. See online resource for exten-
sive clinical descriptions (online resource 2). Overall, all pa-
tients had normal development before seizure onset, occurring
between 5 and 10 months of age, except for patient E. This
patient had a delay in speech development, like his father,
before onset of seizures and seizure onset occurred later, at
31 months. First seizure types were generalized clonic or clus-
ters of focal or complex partial seizures. Later seizures were
mainly complex partial seizures and primary or secondary
generalized clonic and tonic-clonic seizures. In all five pa-
tients, seizures tended to cluster and could be provoked by
fever. Four out of five patients had mild to severe ID, autism
and additional behavioural problems.
Discussion
We here report five male patients with mosaic PCDH19 likely
pathogenic variants, which raises the total number of de-
scribed male patients to nine [2, 13, 14]. Four of the currently
described male patients are the oldest reported so far (ages 10,
13 twice and 14 years old), which gives the opportunity to
investigate whether PCDH19-related phenotypes evolve the
same way in male and female patients. Our current findings
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confirm previously reported observations of similar clinical
features in male and female patients, also for older children
[2, 13, 14]. Focal seizures with affective symptoms (fearful
screaming) are very common in female patients and become
more prevalent with an increasing age [26]. This distinctive
seizure type is also reported in three male patients [14, current
study]. These similarities suggest that there are no differences
in clinical consequences between phenotypes caused by
postzygotic PCDH19 pathogenic variants in mosaic males,
and phenotypes caused by heterozygous PCDH19 pathogenic
variants in females. This lends further support to the hypoth-
esis that cellular interference is the main disease mechanism,
as proposed by Depienne et al. [2] The increasing number of
affectedmosaicmale patients undermines the theory of a com-
pensating effect by the nonparalogousPCDH11Y gene inmale
patients, as proposed by Dibbens et al. [1]. It is highly unlikely
that this gene would only compensate for a complete absence
ofPCDH19 in hemizygous affectedmales, but not for a partial
loss of PCDH19 in mosaic males.
In female patients, seizure frequency often diminishes
around puberty [3, 5, 11, 28–30], possibly due to hormonal
changes [30]. Our 13-year old patient has been seizure free
since the age of 10 years old; our 10-year-old patient only has
one cluster of seizures per year. However, our other 13- and 14-
year-old patients still have ongoing seizures. Although four of
ourmale patients are the oldest reported until now, none of them
has reached adolescence yet, and the numbers are still small,
making it hard to draw definite conclusions. Nevertheless, since
some of the few reported male patients already show a reduc-
tion in seizure frequency with increasing age, it seems unlikely
that a declining seizure frequency is exclusively occurring in
females and is related to female specific hormones.
We hypothesised that males with a mutated allele percent-
age around 50% in the brain, who would have an inherent
high level of cellular interference, may show a more severe
clinical picture than males with a lower or higher percentage
of mosaicism. High or low percentages of mosaicism would
resemble skewed X-inactivation in female patients, which has
also been suggested to lead to a milder phenotype [5, 15],
although no clear correlation has been shown [25, 29].
Indeed, in our cohort, the three patients with the lowest and
highest percentages of mosaicism in blood are the least severe-
ly affected (patients B, D and E), and two previously described
patients, one with borderline ID and one with normal intelli-
gence showed percentages of mosaicism of 10 and 90%, re-
spectively (patients H and I). However, patient G shows an
equal number of mutated and wild-type alleles in blood and is
also mildly affected, and patient F shows no mosaicism in
blood cells at all, only in fibroblasts, but has moderate to
severe ID and ongoing seizures. It is thus not possible to
predict the phenotype based on the percentage of mosaicism
in blood, most likely because it does not necessarily equal the
percentage of mosaicism in the brain.
The number of identified male patients mosaic for
PCDH19 pathogenic variants increases [2, 13, 14], probably
due to our improving abilities to detect mosaicism in general
by using NGS techniques. It is now clear that PCDH19 path-
ogenic variants can cause epilepsy both in males and females
and that mosaicism for PCDH19 pathogenic variants in males
might be more common than previously thought. Because our
five described patients were gathered through personal com-
munication between authors from different diagnostic centres,
no structured cohort with clearly defined inclusion criteria was
tested, which makes it difficult to estimate the frequency of
mosaic pathogenic PCDH19 variants in male patients. Since
the PCDH19 and Dravet syndrome phenotypes show many
similarities, testing a cohort of SCN1A-negative, male Dravet
syndrome patients for mosaic PCDH19 pathogenic variants
could give more insight in the true incidence. In this cohort
and in males with clinical features characteristic of a
PCDH19-related disorder, NGS techniques with high cover-
age should be used to look for PCDH19 pathogenic variants,
as traditional Sanger Sequencing is not sensitive enough to
reliably detect mosaicism. This overview helps create more
knowledge about the disease course in male patients, which
is extremely relevant for counselling those affected and their
families. Reporting on more (older) patients in the future is
essential for establishing a good understanding of prognosis in
male patients.
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